Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?

Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, Andy, Ritchie, David S., Neeson, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382860/
https://www.ncbi.nlm.nih.gov/pubmed/22737619
http://dx.doi.org/10.4161/onci.18963
_version_ 1782236561610375168
author Hsu, Andy
Ritchie, David S.
Neeson, Paul
author_facet Hsu, Andy
Ritchie, David S.
Neeson, Paul
author_sort Hsu, Andy
collection PubMed
description Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fight against this disease.
format Online
Article
Text
id pubmed-3382860
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-33828602012-06-26 Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone? Hsu, Andy Ritchie, David S. Neeson, Paul Oncoimmunology Author's View Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fight against this disease. Landes Bioscience 2012-05-01 /pmc/articles/PMC3382860/ /pubmed/22737619 http://dx.doi.org/10.4161/onci.18963 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Hsu, Andy
Ritchie, David S.
Neeson, Paul
Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
title Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
title_full Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
title_fullStr Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
title_full_unstemmed Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
title_short Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
title_sort are the immuno-stimulatory properties of lenalidomide extinguished by co-administration of dexamethasone?
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3382860/
https://www.ncbi.nlm.nih.gov/pubmed/22737619
http://dx.doi.org/10.4161/onci.18963
work_keys_str_mv AT hsuandy aretheimmunostimulatorypropertiesoflenalidomideextinguishedbycoadministrationofdexamethasone
AT ritchiedavids aretheimmunostimulatorypropertiesoflenalidomideextinguishedbycoadministrationofdexamethasone
AT neesonpaul aretheimmunostimulatorypropertiesoflenalidomideextinguishedbycoadministrationofdexamethasone

Ejemplares similares